KRAS and non-small cell lung carcinoma: In the phase III CheckMate 057 study, NSCLC patients with wild-type EGFR or a KRAS mutation derived a significant OS benefit from nivolumab, whereas those with an EGFR mutation or wild-type KRAS did not [13].